The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-30 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
=== SARS-CoV-2 === Rapamycin has been proposed as a treatment for severe acute respiratory syndrome coronavirus 2 insofar as its immunosuppressive effects could prevent or reduce the cytokine storm seen in very serious cases of COVID-19. Moreover, inhibition of cell proliferation by rapamycin could reduce viral replication.
=== Jabir ibn Hayyan, Abu Bakr al-Razi, Ibn Sina, et al. === The Jabirian authors and al-Razi experimented extensively with the distillation of various substances, including vitriols. In one recipe recorded in his Kitāb al-Asrār ('Book of Secrets'), al-Razi may have created sulfuric acid without being aware of it:
The International Rice Research Institute and the International Maize and Wheat Improvement Center are part of a consortium of agricultural research organizations known as CGIAR. Costing around $600 million, over 50 years, the revolution brought new farming technology, increased productivity, expanded crop yields and mass fertilization to many countries throughout the world. Later it funded over $100 million of plant biotechnology research and trained over four hundred scientists from Asia, Africa and Latin America. It also invested in the production of transgenic crops, including rice and maize. In 1999, the then president Gordon Conway addressed the Monsanto Company board of directors, warning of the possible social and environmental dangers of this biotechnology, and requesting them to disavow the use of so-called terminator genes; the company later complied. In the 1990s, the foundation shifted its agriculture work and emphasis to Africa; in 2006, it joined with the Bill & Melinda Gates Foundation in a $150 million effort to fight hunger in the continent through improved agricultural productivity. In an interview marking the 100 year anniversary of the Rockefeller Foundation, Judith Rodin explained to This Is Africa that Rockefeller has been involved in Africa since their beginning in three main areas – health, agriculture and education, though agriculture has been and continues to be their largest investment in Africa.
micronucleus The smaller of the two types of nuclei that occur in pairs in the cells of some ciliated protozoa. Whereas the larger macronucleus is polyploid, the micronucleus is diploid and generally transcriptionally inactive except for the purpose of sexual reproduction, where it has important functions during conjugation.
Sources: en.wikipedia.org
=== Extracellular matrix === Granzyme B can degrade many proteins in the extracellular matrix (ECM) including fibronectin, vitronectin and aggrecan. Cleavage can cause cell death by anoikis and release alarmins from the ECM inducing inflammation. Fragments of fibronectin can attract neutrophils and stimulate MMP expression from chondrocytes. Basophils secrete granzyme B to degrade endothelial cell-cell contacts allowing extravasation to sites of inflammation. Granzyme B can also induce inflammation by processing cytokines IL-1α and IL18. It can also trigger the release of IL6 and IL8 through activation of PAR1 (Protease activated receptor 1). Cleavage of vitronectin occurs at the RGD integrin binding site interrupting cell growth signalling pathways. Cleavage of laminin and fibronectin disrupts dermal-epidermal junction attachment and cross talk while decorin destruction by granzyme B causes collagen disorganisation, skin thinning and aging. Keratinocytes can express granzyme B after exposure to UVA and UVB which is linked to photoaging of the skin. Granzyme B can also impair wound healing. Cleavage of the von Willebrand factor inhibits platelet aggregation and of plasminogen produces an angiostatin fragment preventing angiogenesis. The cutting of fibronectins and vitronectins delays the formation of a provisional matrix impairing wound healing further.
Melo's government also became known for his large-scale program of the concession of programs and public spaces to private initiatives, saying that the privatization program "is in the DNA" of his government. It was put forth that the municipality did not have the conditions to maintain these services adequately and that the partnerships would bring qualified individuals to the system and health benefits for the population. During his electoral campaign, he declared that services should be public, but backed up by private partnerships. Places for the dispersion of the equipment included Auditório Araújo Viana, Teatro de Câmara Túlio Piva, Parque da Harmonia, and stretch 1 of the Orla do Guaíba, some of them completing a process started during the previous administration. They had expected new concessions at Farroupilha, Moinhos de Vento and Marinha do Brasil parks; from stretches 2 and 3 of the Orla do Guaíba; Hospital de Pronto Socorro and Hospital Materno-Infantil Presidente Vargas; the Usina do Gasômetro; with garbage collection and water and sewage treatment; green areas in the surrounding areas of the Aeromóvel and the area around the Joaquim Felizardo Museum of Porto Alegre. The public transport company Carris was privatized, with its assets being sold. The program came to be criticized for devaluing the public character of services and spaces, and to allow them to be exploited commercially, along with the program's proposals having little transparency and without the necessary dialogue with the community.
=== Enzymatic hydrolysis === For the production process of enzymatic HVP, enzymes are used to break down the proteins. To break down the protein to amino acids, proteases are added to the mixture of defatted protein and water. Due to the sensitivity of enzymes to a specific pH, either an acid or a base is added to match the optimum pH. Depending on the activity of the enzymes, up to 24 hours are needed to break down the proteins. The mixture is heated to inactivate the enzymes and then filtered to remove the insoluble carbohydrates (humin). Since no salt is formed during the production process, manufacturers may add salt to eHVP preparations to extend shelf life or to provide a product similar to conventional aHVP. A vendor source states that salt is conventionally added before eHVP production to control microbial growth. With acid-tolerant enzymes, some of the salt can be replaced with a small amount of an acid (patent literature mentioning the acid-tolerant enzyme suggests a reaction pH of 4) to reduce sodium content.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.